Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16888285 | 1.00 | RORC (1.00) | RORCNR1I2 | |
| SCHEMBL16888284 | 1.00 | RORC (1.00) | RORCNR1I2 | |
| SCHEMBL16891806 | 0.95 | RORC (1.00) | RORCNR1I2 | |
| SCHEMBL16891716 | 0.95 | RORC (1.00) | RORCNR1I2 | |
| SCHEMBL16880558 | 0.91 | RORC (0.92) | RORCNR1I2 | |
| SCHEMBL18204941 | 0.91 | RORC (0.83) | RORCNR1I2 | |
| SCHEMBL16888296 | 0.91 | RORC (0.83) | RORCNR1I2 | |
| SCHEMBL16877049 | 0.91 | RORC (0.83) | RORCNR1I2 | |
| SCHEMBL16891798 | 0.89 | RORC (1.00) | RORCNR1I2 | |
| SCHEMBL16891760 | 0.89 | RORC (1.00) | RORCNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3092215-B1 | CYCLOHEXYL SULFONE ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9708253-B2 | Cyclohexyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708253-B2 | Cyclohexyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708253-B2 | Cyclohexyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-07-18 | — | — | US | disclosed |
| EP-3092215-A1 | CYCLOHEXYL SULFONE ROR MODULATORS | Bristol-Myers Squibb Company (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160326104-A1 | CYCLOHEXYL SULFONE ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| WO-2015103507-A1 | CYCLOHEXYL SULFONE RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103507-A1 | CYCLOHEXYL SULFONE RORϒ MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326104-A1 | CYCLOHEXYL SULFONE ROR GAMMA MODULATORS | RORB, RORC, RORA | RORC 2/4885NR1I2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.